Clinical trials: Pulmonary Resistance
Sars-CoV2, Critical Illness
COVID-19 and ICU-acquired MDR Bacteria
This multicenter before-after study aimed to determine the impact of infection related to SARS-CoV-2 on the incidence of ICU-acquired multidrug resistant (MDR) bacteria.
- Trial name
- COVID-BMR (NCT04378842)
- Where
- 7 sites in France
- Volunteers
- 368 people
- Sponsor
- University Hospital, Lille
Lung Cancer
Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy
The investigators plan to conduct a multiomics analysis（such as, Genomics, proteomics, single cell RNA sequencing, space transcriptomics）of tumor tissue and blood, aiming at analyzing tumor heterogeneity, mapping the…
- Trial name
- NCT05636605
- Testing
- Multiomics analysis
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
COPD
Refractory Breathlessness in COPD
This study aims to investigate the prognosis and clinical outcomes of patients with chronic obstructive pulmonary disease (COPD) who continue to experience refractory dyspnea despite treatment with long-acting beta-agonist (LABA)…
- Trial name
- RB-COPD (NCT07160322)
- Where
- South Korea
- Volunteers
- 730 people
- Sponsor
- Seoul National University
Cystic Fibrosis
Cystic Fibrosis (CF) Flow Rates Study
We wish to measure the inspiratory flow and volumes generated by the subjects inhaling from a spirometer with a high resistance dry powder inhaler in series in subjects with cystic fibrosis.
- Trial name
- NCT00779077
- Volunteers
- 25 people
- Sponsor
- Syntara
Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP)
Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
This Phase IIb study aims to evaluate the safety and efficacy of BV100 in combination with low dose polymyxin B plus ceftazidime/avibactam or cefiderocol in patients with suspected or confirmed CRABC infections.
- Conditions
- Ventilator Associated Bacterial Pneumonia (VABP), Hospital Acquired Bacterial Pneumonia (HABP), Blood Stream Infection, Meningitis, Bacterial
- Trial name
- RIV- CARE (NCT07431307)
- Testing
- BV100 with 50 mg polymyxin B plus ceftazidime/avibactam, BV100 with 50 mg polymyxin B plus cefiderocol, Best Available Therapy (BAT)
- Volunteers
- 120 people
- Sponsor
- BioVersys AG
Tuberculosis
Multi-Drug Resistant Tuberculosis in Korea
This study, conducted in Korea, will examine why some people are more susceptible to tuberculosis (TB) than others and why some strains of M tuberculosis (the bacteria that causes TB) are more difficult to treat or become…
- Trial name
- NCT00341601
- Where
- 2 sites in South Korea
- Volunteers
- 777 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disorder and Acute Exercise
For this study a resistance bout will be performed in order to promote the robust response of protein synthesis. Type II muscle fibers often exhibit more atrophy than type I fibers in COPD subjects therefore specifically…
- Trial name
- NCT02780219
- Testing
- stable amino acid infusion, acute exercise with amino acid infusion, 24-hour post exercise amino acid infusion
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
For patients of advanced NSCLC (non small cell lung cancer) , Individualized cancer therapy has been widely accepted since the success of crizotinib administration based on EML4-ALK fusion gene detection and gefitinib and…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation, EGFR-TKI Sensitizing Mutation, Germline Mutations
- Trial name
- NCT01994057
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sun Yat-sen University
Advanced Non-small-cell Lung Cancer
Tislelizumab as Cross-line Treatment for Advanced NSCLC
This study is a single-arm, prospective, open phase II clinical study, exploring the efficacy and safety for advanced non-small cell lung cancer after progression of first-line Tislelizumab combined with chemotherapy and…
- Trial name
- NCT05192681
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Covid19, Personal Protective Equipment
Rational Use of Personal Protective Equipment During COVID-19 Pandemic
This study aims to improve the personal protective equipment (PPE) used while treating patients with COVID-19, to protect staff and avoid cross-infection of patients.
- Trial name
- RUPERT (NCT04712045)
- Testing
- New PPE, Old PPE
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Lung Cancer, Non-small Cell, EGFR Gene Mutation
Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Lung cancer is currently the world's largest malignant tumor for cancer-related deaths with non-small cell lung cancer (NSCLC) accounting for 80%-85%.
- Conditions
- Lung Cancer, Non-small Cell, EGFR Gene Mutation, EGFR-TKI Resistant Mutation, Primary Resistance
- Trial name
- PRECISE (NCT05598528)
- Testing
- Genomic profiles detection, circulating tumor DNA detection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Second Xiangya Hospital of Central South University
Asthma, Obesity
Obesity, Metabolic Dysregulation and the Airway Epithelium in Asthmatics
The objective of this pilot study is to determine whether obesity and metabolic syndrome are in fact synergistic in relation to airway nitric oxide (NO) biology.
- Conditions
- Asthma, Obesity, Metabolic Syndrome
- Trial name
- NCT03215836
- Testing
- Bronchoscopy and Nasal Epithelium Brush Sampling
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Colorado, Denver
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non Small Cell Lung Cancer
Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs
The study is aimed at patients with advanced cancer and EGFR mutation. Some molecules recently discovered at the level of tumor tissue can influence the response to anti-EGFR drugs.
- Trial name
- NCT06863818
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
High Altitude, Healthy Adult
Assessment of Total Pulmonary Resistance sPAP/CO Between High Altitude HA vs. Sea Level LA in Healthy Individuals H
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on pulmonary resistance (sPAP/CO) and other hemodynamic outcomes in healthy individuals, who live permanently >2600m.
- Conditions
- High Altitude, Healthy Adult, Echocardiography, Pulmonary Resistance
- Trial name
- NCT07804485
- Testing
- Descent from 2850m to sea level
- Where
- Switzerland
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Silvia Ulrich Somaini
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
- Trial name
- Re-PHIRE (NCT05737940)
- Testing
- AZD3427
- Where
- 60 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- AstraZeneca
IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy
Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance
This is an open-label, single-arm, multi-center, phase II exploratory study that evaluates the efficacy and safety of Toripalimab injection (JS001) combined with Pemetrexed and Anlotinib as a second-line treatment for patients…
- Trial name
- NCT04316351
- Testing
- Toripalimab + Pemetrexed + Anlotinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Cystic Fibrosis, Pseudomonas Aeruginosa
A Comparator Study Evaluating Microbiological Resistance and Effects of Alternating Inhaled Antibiotic Therapies
This is a pilot study of inhaled antibiotic regimens is a pilot study examining clinical and laboratory endpoints of patients on inhaled antibiotic treatments.
- Trial name
- NCT01319253
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Indiana University
Pneumonitis, Acinetobacter Baumannii
A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia
This study intends to evaluate the efficacy and safety of eravacycline-based combination therapy in real words for Chinese patients with CRAB pneumonia, providing data reference for clinical treatment of CRAB pneumonia.
- Trial name
- NCT06670872
- Testing
- Eravacycline combination therapy group
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
This phase I trial tests the safety, side effects, and best dose of osimertinib, cetuximab, and tucatinib in treating patients with EFGR-mutant non-small cell lung cancer that is stage IV or has come back (recurrent).
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT06067776
- Testing
- Cetuximab, Osimertinib, Tucatinib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Jonathan Riess